NEUROCRINE BIOSCIENCES INC
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Neurocrine Biosciences develops and markets treatments for neurological and endocrine-related disorders, including drugs for tardive dyskinesia, Parkinson's disease, and congenital adrenal hyperplasia. Its commercial product Ingrezza treats movement disorders, and the company also has a pipeline targeting conditions such as schizophrenia and endometriosis-related pain.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ABERNETHY MATTChief Financial Officer | Sell | $363K | 2,311at $157.20 | Sep 14, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable NBIX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.